Edition:
Deutschland

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,676JPY
18 May 2018
Change (% chg)

¥0 (+0.00%)
Prev Close
¥1,676
Open
¥1,688
Day's High
¥1,688
Day's Low
¥1,674
Volume
6,799,500
Avg. Vol
7,872,678
52-wk High
¥1,688
52-wk Low
¥1,332

4503.T

Chart for 4503.T

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive... (more)

Buy/Sell

Sell Hold Buy
2.58 Mean rating from 12 analysts

Overall

Beta: 0.60
Market Cap(Mil.): ¥3,012,207.00
Shares Outstanding(Mil.): 2,068.82
Dividend: 18.00
Yield (%): 2.34

BRIEF-Aquinox And Astellas Announce Exclusive Licensing Agreement For Rosiptor In Asia-Pacific Region Including Japan

* AQUINOX AND ASTELLAS ANNOUNCE EXCLUSIVE LICENSING AGREEMENT FOR ROSIPTOR IN ASIA-PACIFIC REGION INCLUDING JAPAN

BRIEF-FDA Approves Supplemental New Drug Application For Myrbetriq For Treatment Of Overactive Bladder Symptoms

* FDA APPROVES SUPPLEMENTAL NEW DRUG APPLICATION FOR MYRBETRIQ® (MIRABEGRON) FOR USE IN COMBINATION WITH SOLIFENACIN SUCCINATE FOR THE TREATMENT OF OVERACTIVE BLADDER SYMPTOMS

BRIEF-Astellas Pharma to retire treasury shares

* Says it will retire 89 million shares(4.3 percent stake) of its common stock on May 31

BRIEF-Astellas Says To Cancel Treasury Stock Equivalent To 4.3 Percent Of Shares Outstanding

* ASTELLAS SAYS TO CANCEL TREASURY STOCK EQUIVALENT TO 4.3 PERCENT OF SHARES OUTSTANDING Further company coverage: (Reporting By Chris Gallagher)

BRIEF-Astellas Pharma Submits NDA For Approval Of Gilteritinib

* ASTELLAS SUBMITS NEW DRUG APPLICATIONS FOR APPROVAL OF GILTERITINIB FOR THE TREATMENT OF FLT3MUT+ RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

BRIEF-Proteostasis Therapeutics - Co & Astellas Pharma Entered Into Amendment No. 6 To Collaboration & License Agreement

* PROTEOSTASIS THERAPEUTICS - ON APRIL 20, CO & ASTELLAS PHARMA ENTERED INTO AMENDMENT NO. 6 TO COLLABORATION & LICENSE AGREEMENT DATED NOVEMBER 4, 2014

BRIEF-Astellas Announces Sale Of Certain Agensys Research Facilities To Kite, A Gilead Co

* ASTELLAS ANNOUNCES SALE OF CERTAIN AGENSYS RESEARCH FACILITIES TO KITE, A GILEAD COMPANY

BRIEF-Cardurion Pharmaceuticals Licenses Clinical Stage Heart Failure Candidate From Astellas

* CARDURION PHARMACEUTICALS LICENSES CLINICAL STAGE HEART FAILURE CANDIDATE FROM ASTELLAS

BRIEF-Seattle Genetics And Astellas Receive FDA Breakthrough Therapy Designation For Enfortumab Vedotin

* SEATTLE GENETICS AND ASTELLAS RECEIVE FDA BREAKTHROUGH THERAPY DESIGNATION FOR ENFORTUMAB VEDOTIN IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie +0.03%
Rohstoffe +0.31%
Industrie -0.07%
Konjunktur abhängige Waren & Dienstleistungen -0.44%
Konjunktur unabhängige Waren & Dienstleistungen -0.55%
Finanzindustrie +0.23%
Pharma -0.34%
Technologie -0.57%
Telekommunikation -0.07%

Nachrichten aus der Wirtschaft